Modus Therapeutics publishes interim report for the second quarter 2021

STOCKHOLM, SWEDEN - 19 august 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the second quarter 2021. The interim report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.

The second quarter in figures

  • The loss after tax amounted to TSEK 2,533 (1,698).
  • Cash flow from operating activities amounted to TSEK -2,299 (-2,267)
  • Cash and cash equivalents amounted to TSEK 3,830 (4,395)

The first half-year in figures

  • The loss after tax amounted to TSEK 3,961 (4,303).
  • Cash flow from operating activities amounted to TSEK -3,465 (-5,181)
  • Cash and cash equivalents amounted to TSEK 3,830 (4,395)

Important events during the second quarter

  • Modus held its Annual General Meeting on May 3, 2021.
  • Modus Therapeutics and Imperial College London Sign Clinical Collaboration Targeting Severe Malaria.
  • New issue in connection with listing on Nasdaq First North.

Important events after the end of the second quarter

  • Modus Therapeutics issue was oversubscribed, and the company was approved for listing on Nasdaq First North.

This information is such information that Modus Therapeutics Holding AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on August 19, 2021.

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Subscribe

Documents & Links